Revolution in cancer therapy to be driven by new diagnostics. Histology, genomics and liquid biopsy converge. COVID-19 changes focus.
This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
A revolution in cancer therapy is underway. New therapy based on using the body’s natural immune defenses is having unprecedented success. But diagnostics, especially biomarkers are desperately needed to help select the right therapy.
The technology is moving faster than the market. The impact on the health care industry is enormous. Tumor Mutational Burden? Checkpoint Inhibitors? Cytokines? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.